Crossmark

A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1007/s00432-023-04775-2

Published Online: 2023-05-16

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zeng, Xianghua

Jia, Yingxin

Chen, Hongmei

Luo, Qinli

Zhao, Huakan

Liang, Guanzhong

Chen, Wen

Li, Yongsheng
Funding

Funding for this research was provided by:

Scientific research project of Chongqing Medical Biotechnology Association (cmba2022kyym-skxmG006)

Scientific research project of Chongqing Medical Biotechnology Association (cmba2022kyym-skxmG006)

Scientific research project of Chongqing Medical Biotechnology Association (cmba2022kyym-skxmG006)

Scientific research project of Chongqing Medical Biotechnology Association (cmba2022kyym-skxmG006)

Scientific research project of Chongqing Medical Biotechnology Association (cmba2022kyym-skxmG006)

Decision Consultation Management Innovation Project of Shapingba District (Jcd202278)

Decision Consultation Management Innovation Project of Shapingba District (Jcd202278)

Decision Consultation Management Innovation Project of Shapingba District (Jcd202278)

Decision Consultation Management Innovation Project of Shapingba District (Jcd202278)

Decision Consultation Management Innovation Project of Shapingba District (Jcd202278)
License Information

Text and Data Mining valid from 2023-05-16

Version of Record valid from 2023-05-16
More Information

Article History

Received: 2 April 2023

Accepted: 10 April 2023

First Online: 16 May 2023

Declarations

:

: The authors declared that they had no financial interests.

Document is current

Any future updates will be listed below